Raloxifene is an effective option for the prevention of vertebral fractures associated with postmenopausal osteoporosis

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.20, Iss.11, 2004-11, pp. : 1-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Multi-Therapy Treatment Strategies in the Prevention of Vertebral Fractures in Postmenopausal Women with Osteoporosis

By Rosner A.J.

PharmacoEconomics, Vol. 14, Iss. 5, 1998-11 ,pp. : 559-573

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Raloxifene in Postmenopausal Osteoporosis

By Cranney Ann

Drug Safety, Vol. 28, Iss. 8, 2005-01 ,pp. : 721-730

Adis International

Access to resources Recommend Favorite

Raloxifene: A Review of its Use in Postmenopausal Osteoporosis

By Clemett D. Spencer C.M.

Drugs, Vol. 60, Iss. 2, 2000-08 ,pp. : 379-411

Adis International

Access to resources Recommend Favorite

Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene

By Ko Seung Sang Jordan V Craig

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 4, 2011-03 ,pp. : 657-674

Informa Healthcare

Access to resources Recommend Favorite

Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 1081-1081

Informa Healthcare

Access to resources Recommend Favorite